Last edition
News about Ingredients
Evonik Expands Excipients Portfolio, Launches MaxiPure Polysorbate 80 for Injectable Formulations
Engineered to meet the stringent demands of modern drug development, Evonik's MaxiPure Polysorbate 80 addresses key challenges such as protein stability, viral inactivation, and the consistent solubilisation of hydrophobic active pharmaceutical ingredients (APIs).
Ingredients | 24/09/2025 | By Dineshwori | 200
The first participant has been dosed in the pivotal Phase III exPDite-2 trial of bemdaneprocel, an investigational cell therapy, while the first European participants have been enrolled in REGENERATE-PD, a Phase II trial of the gene therapy AB-1005.
Ingredients | 23/09/2025 | By Darshana | 369
Kashiv BioSciences and CRISTALIA Partner to Bring Omalizumab Biosimilar to Latin America
Kashiv BioSciences, LLC (Kashiv), a US-based vertically integrated biopharmaceutical company, has entered into a licensing and supply agreement with CRISTÁLIA, one of Brazil’s leading pharmaceutical companies, to commercialize ADL-018 / bOmalizumab, a proposed biosimilar to Xolair, in Latin America (LATAM).
Ingredients | 14/09/2025 | By Darshana | 432
The Bulk Drug Park at Una in Himachal Pradesh has received environmental clearance from the Union Ministry of Environment, Forest and Climate Change, a key milestone for India’s pharmaceutical infrastructure.
Ingredients | 13/09/2025 | By Darshana | 620
BioNxt Begins Lab-Scale ODF Development After Receiving Semaglutide API
BioNxt Solutions has received the Semaglutide active pharmaceutical ingredient (API), enabling the initiation of laboratory-scale formulation and testing of its oral dissolvable film (ODF) delivery system.
Ingredients | 03/09/2025 | By Dineshwori | 488
India Emerges as Global Manufacturing Powerhouse in Life Sciences: EY Report
India is fast becoming a global hub for life sciences Global Capability Centres (GCCs), according to the latest EY report. Nearly half of the world's top 50 life sciences firms now operate GCCs in the country, amounting to around 100 centres, with plans to scale this number to 160 over the next five years.
Ingredients | 03/09/2025 | By Darshana | 265
India's Push for API Self-Reliance Under the PLI Scheme
India’s Production Linked Incentive (PLI) scheme for bulk drugs and key starting materials is transforming the country’s pharmaceutical manufacturing landscape, pushing the sector toward self-reliance.
Ingredients | 31/08/2025 | By Darshana | 1902
UCB, a global biopharmaceutical company, announced it will present 26 abstracts from its epilepsy portfolio at the upcoming International Epilepsy Congress (IEC) in Lisbon, Portugal, from August 30 to September 3, 2025.
Ingredients | 30/08/2025 | By Darshana | 210
Zydus Reports Positive Phase 3 Results for Saroglitazar in Primary Biliary Cholangitis
The study met its primary endpoint, showing a 48.5% treatment difference in biochemical response with Saroglitazar 1 mg compared to placebo (P<0.001). Biochemical response was defined by improvement in alkaline phosphatase (ALP) and bilirubin, key markers of PBC progression.
Ingredients | 29/08/2025 | By Darshana | 141
Lupin Partners with Sandoz to Market Biosimilar Ranibizumab Across Global Markets
Lupin has entered into an agreement with Switzerland-based Sandoz Group AG to market and commercialise its biosimilar ranibizumab in multiple international markets.
Ingredients | 13/08/2025 | By Darshana | 171
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy